Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin)–typically used in combination with chemotherapy. However, a new study by researchers at Fox Chase Cancer Center reports that it may be safe to treat these patients with both Trastuzumab and adjuvant radiation therapy.
The study will be presented at the annual meeting of the American Society for Radiation Oncology (ASTRO).
» Read more: Terramed Alliance News Safe To Treat HER2-positive Breast Cancer